Maria Kristiansen

Ms. Maria Kristiansen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2018 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KTKirstine S Tølbøl
Kirstine S Tølbøl
MKMaria Kristiansen
Maria Kristiansen
HHHenrik H Hansen
Henrik H Hansen
SVSanne S Veidal
Sanne S Veidal
KRKristoffer Tg Rigbolt
Kristoffer Tg Rigbolt
MFMichael Feigh
Michael Feigh
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

1 January 2016 in World Journal of Hepatology
Verified
Journal Article
Open access
MKMaria Kristiansen
Maria Kristiansen
SVSanne Skovgård Veidal
Sanne Skovgård Veidal
KRKristoffer Tobias Gustav Rigbolt
Kristoffer Tobias Gustav Rigbolt
KTKirstine Sloth Tølbøl
Kirstine Sloth Tølbøl
JRJonathan David Roth
Jonathan David Roth
MFMichael Feigh
Michael Feigh
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy

1 January 2019 in Lipids
Verified
Journal Article
Closed access
PDF file
MKMaria Kristiansen
Maria Kristiansen
SVSanne S. Veidal
Sanne S. Veidal
CCChristina Christoffersen
Christina Christoffersen
JJJacob Jelsing
Jacob Jelsing
KRKristoffer T. G. Rigbolt
Kristoffer T. G. Rigbolt

3 December 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
MKMaria Kristiansen
Maria Kristiansen
BSBirgit Stierstorfer
Birgit Stierstorfer
JRJörg F. Rippmann
Jörg F. Rippmann
SVSanne S. Veidal
Sanne S. Veidal
KRKristoffer T. G. Rigbolt
Kristoffer T. G. Rigbolt
ABAndre Broermann
Andre Broermann
There is a marked need for improved animal models of nonalcoholic steatohepatitis (NASH) to facilitate the development of more efficacious drug therapies for the disease.

28 December 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MKMaria Kristiansen
Maria Kristiansen
SVSanne Skovgård Veidal
Sanne Skovgård Veidal
CCChristina Christoffersen
Christina Christoffersen
MFMichael Feigh
Michael Feigh
NVNiels Vrang
Niels Vrang
JJJacob Jelsing
Jacob Jelsing
Background: Compounds in clinical development for nonalcoholic steatohepatitis (NASH) improve liver histopathology in diet-induced obese mouse models of biopsy-confirmed NASH. Since the biopsy section used for histopathological evaluation represents only < 1% of the whole mouse liver, we evaluated how well biopsy-based quantitative image analyses correlate to stereology-based whole-liver quantitative changes upon drug treatment. Methods: Male leptin-deficient Lepob/Lepob mice were fed the Amylin liver NASH (AMLN) diet for 16 weeks before stratification into treatment groups using a biopsy-based evaluation of type I collagen αI (col1a1) levels. Mice were treated for 8 weeks with either vehicle (PO, QD), liraglutide (0.4 mg/kg, SC, QD), elafibranor (30 mg/kg, PO, QD) or INT-767 (10 mg/kg, PO, QD). Terminal quantitative histological assessment of liver lipid (hematoxylin-eosin staining), inflammation (galectin-3 immunohistochemistry (IHC); gal-3), and fibrosis (col1a1 IHC) was performed on terminal liver biopsies and compared with stereologically sampled serial sections spanning the medial, left and right lateral lobe of the liver. Results: The distribution of liver lipid and fibrosis was markedly consistent across lobes, whereas inflammation showed some variability. While INT-767 and liraglutide significantly reduced total liver weight by 20 and 48%, respectively, elafibranor tended to exacerbate hepatomegaly in Lepob/Lepob-NASH mice. All three compounds markedly reduced biopsy-based relative liver lipid content. Elafibranor and INT-767 significantly reduced biopsy-based relative gal-3 levels (P < 0.001), whereas INT-767 and liraglutide tended to reduce relative col1a1 levels. When changes in liver weight was accounted for, both INT-767 and liraglutide significantly reduced biopsy-based total col1a1 content. Although minor differences in absolute and relative liver lipid, inflammation and fibrosis levels were observed across lobes, the interpretation of drug-induced effects were consistent with biopsy-based conclusions. Notably, the incorporation of changes in total liver mass revealed that liraglutide’s efficacy reached statistical significances for all analyzed parameters. Conclusions: In conclusion, in-depth analyses of liver homogeneity demonstrated that drug-induced improvement in liver biopsy-assessed histopathology is representative for overall liver effects assessed using stereology. Importantly, these findings reveal how changes in whole-liver mass should be considered to provide a deeper understanding of apparent drug treatment efficacy in preclinical NASH studies.

24 May 2013
Verified
Journal Article
Closed access
EVEfstathios Vassiliadis
Efstathios Vassiliadis
SVSanne Skovgaard Veidal
Sanne Skovgaard Veidal
MKMaria Kristiansen
Maria Kristiansen
CHChristina Hansen
Christina Hansen
MJMia Jorgensen
Mia Jorgensen
MKMorten Karsdal
Morten Karsdal